Terms: = Leukemia AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR
563 results:
1. Comprehensive characterization of immunogenic cell death in acute myeloid leukemia revealing the association with prognosis and tumor immune microenvironment.
Chen Y; Qiu X; Liu R
BMC Med Genomics; 2024 Apr; 17(1):107. PubMed ID: 38671491
[TBL] [Abstract] [Full Text] [Related]
2. Methodological challenges in the development of endpoints for myelofibrosis clinical trials.
Barosi G; Tefferi A; Gangat N; Szuber N; Rambaldi A; Odenike O; Kröger N; Gagelmann N; Talpaz M; Kantarjian H; Gale RP
Lancet Haematol; 2024 May; 11(5):e383-e389. PubMed ID: 38604205
[TBL] [Abstract] [Full Text] [Related]
3. Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.
Ferrer-Marín F; Hernández-Boluda JC; Alvarez-Larrán A
Br J Haematol; 2024 May; 204(5):1605-1616. PubMed ID: 38586911
[TBL] [Abstract] [Full Text] [Related]
4. Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial.
van der Maas NG; Versluis J; Nasserinejad K; van Rosmalen J; Pabst T; Maertens J; Breems D; Manz M; Cloos J; Ossenkoppele GJ; Floisand Y; Gradowska P; Löwenberg B; Huls G; Postmus D; Pignatti F; Cornelissen JJ
Blood Cancer J; 2024 Mar; 14(1):56. PubMed ID: 38538587
[TBL] [Abstract] [Full Text] [Related]
5. Impact of
Narlı Özdemir Z; İpek Y; Patır P; Ermiş G; Çiftçiler R; Özmen D; Baysal M; Gürsoy V; Yıldızhan E; Güven S; Ercan T; Elibol T; Mersin S; Genç E; Davulcu EA; Karakuş V; Erkut N; Güneş G; Diz Küçükkaya R; Eşkazan AE
Turk J Haematol; 2024 Mar; 41(1):26-36. PubMed ID: 38433449
[TBL] [Abstract] [Full Text] [Related]
6. [Clinical and prognostic characteristics of pediatric acute myeloid leukemia with myelodysplasia-related changes under different diagnostic criteria].
Zhang RR; Ruan M; Liu TF; Wang SC; Zhang XY; Qi BQ; Zhu XF; Zhang L
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(3):250-255. PubMed ID: 38378287
[No Abstract] [Full Text] [Related]
7. Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study.
England JT; Szuber N; Sirhan S; Dunne T; Cerquozzi S; Hill M; Villeneuve PJA; Ho JM; Sadikovic B; Bhai P; Krishnan N; Dowhanik S; Hillis C; Capo-Chichi JM; Tsui H; Cheung V; Gauthier K; Sibai H; Davidson MB; Bankar A; Kotchetkov R; Gupta V; Maze D
Leukemia; 2024 Mar; 38(3):570-578. PubMed ID: 38321107
[TBL] [Abstract] [Full Text] [Related]
8. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
9. One thousand patients with essential thrombocythemia: the Mayo Clinic experience.
Gangat N; Karrar O; Al-Kali A; Begna KH; Elliott MA; Wolanskyj-Spinner AP; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Blood Cancer J; 2024 Jan; 14(1):11. PubMed ID: 38238303
[TBL] [Abstract] [Full Text] [Related]
10. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.
Loscocco GG; Gesullo F; Capecchi G; Atanasio A; Maccari C; Mannelli F; Vannucchi AM; Guglielmelli P
Blood Cancer J; 2024 Jan; 14(1):10. PubMed ID: 38238287
[TBL] [Abstract] [Full Text] [Related]
11. Occupational-related exposure to diesel exhaust and risk of leukemia: systematic review and meta-analysis of cohort studies.
Shah D; DeStefano V; Collatuzzo G; Teglia F; Boffetta P
Int Arch Occup Environ Health; 2024 Mar; 97(2):165-177. PubMed ID: 38142415
[TBL] [Abstract] [Full Text] [Related]
12. STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient.
Zhang S; Yan J; He L; Jiang Z; Jiang H
Cancer Gene Ther; 2024 Mar; 31(3):484-494. PubMed ID: 38135698
[TBL] [Abstract] [Full Text] [Related]
13. [Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors].
Xu XS; Ding H; Zhang X; Liao Y; Li H; Liu QY; Liu JZ; Zhang L; Huang J; Gong YP; Ma HB; Xiang B; Dai Y; Hou L; Shuai X; Niu T; Wu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):742-748. PubMed ID: 38049318
[No Abstract] [Full Text] [Related]
14. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
Zhang L; Dong H
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
[TBL] [Abstract] [Full Text] [Related]
15. Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (calr) in exon 3.
Bonnet S; Carillo S; Legrand B; Burroni B; Lavabre-Bertrand T; Requirand G; Robert N; Fornero L; Al Mansoori A; Moreaux J; Cartron G; Gabellier L; Herbaux C
Eur J Haematol; 2024 Mar; 112(3):475-478. PubMed ID: 37918825
[TBL] [Abstract] [Full Text] [Related]
16. AMPK activation induces immunogenic cell death in AML.
Mondesir J; Ghisi M; Poillet L; Bossong RA; Kepp O; Kroemer G; Sarry JE; Tamburini J; Lane AA
Blood Adv; 2023 Dec; 7(24):7585-7596. PubMed ID: 37903311
[TBL] [Abstract] [Full Text] [Related]
17. [Role of Flow Cytometry in the Diagnosis of Chronic Myeloid leukemia].
Huang W; Liu RR; Wu YY; Li SS; Tang YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1327-1332. PubMed ID: 37846680
[TBL] [Abstract] [Full Text] [Related]
18. The feasibility of implementing Toronto childhood cancer stage guidelines and estimating the impact on outcome for childhood cancers in seven pediatric oncology units in sub-Saharan Africa. A study from the Franco-African Pediatric Oncology Group.
Mallon B; Kaboré R; Couitchere L; Akonde FB; Narison MLR; Budiongo A; Dackono TA; Pondy A; Diedhiou F; Patte C; Steliarova-Foucher E; Clavel J
Pediatr Blood Cancer; 2023 Dec; 70(12):e30664. PubMed ID: 37732944
[TBL] [Abstract] [Full Text] [Related]
19. A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count.
Tefferi A; Loscocco GG; Farrukh F; Szuber N; Mannelli F; Pardanani A; Hanson CA; Ketterling RP; De Stefano V; Carobbio A; Barbui T; Guglielmelli P; Gangat N; Vannucchi AM
Am J Hematol; 2023 Dec; 98(12):1829-1837. PubMed ID: 37665758
[TBL] [Abstract] [Full Text] [Related]
20. Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.
Murton A; Forsyth C; Ross DM; Grigg A
Leuk Lymphoma; 2023 Dec; 64(12):2018-2025. PubMed ID: 37574855
[TBL] [Abstract] [Full Text] [Related]
[Next]
